CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$278.06
−1.28%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- $2.96
- Revenue estimate
- $958.5M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- $3.02
- EPS estimate
- $2.77
- Revenue actual
- $1.0B
- Revenue estimate
- $980.5M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 11
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -80.6%
- Revenue beats (12Q)
- 11
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $276
- PT range
- $219 – $320
- Analysts
- 9
7 Buy2 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | $2.77 | $3.02 | Beat 9.03% | $1.0B |
| May 7, 2026 | $1.96 | $2.06 | Beat 5.10% | $995.8M |
| Feb 18, 2026 | $2.33 | -$5.62 | Miss -341.17% | $994.2M |
| Nov 5, 2025 | $2.32 | $2.43 | Beat 4.74% | $1.0B |
| Aug 6, 2025 | $2.50 | $3.12 | Beat 24.80% | $1.0B |
| May 7, 2025 | $2.06 | $2.34 | Beat 13.59% | $984.2M |
| Feb 19, 2025 | $2.50 | $2.66 | Beat 6.40% | $1.0B |
| May 9, 2024 | $2.06 | $2.27 | Beat 10.19% | $1.0B |
| Feb 14, 2024 | $2.39 | $2.46 | Beat 2.93% | $1.0B |
| May 11, 2023 | $2.60 | $2.78 | Beat 7.05% | $1.0B |
| Feb 22, 2023 | $2.75 | $2.98 | Beat 8.48% | $1.1B |
| Nov 2, 2022 | $2.52 | $2.63 | Beat 4.45% | $989.2M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026